Implementation of the CTD: CBER’S Perspective May 8, 2001 Joan Wilmarth Blair, M.A. International Affairs Advisor CBER/FDA May 8, 2001 Joan Wilmarth Blair,

Slides:

Advertisements

Similar presentations

CBER Whole Blood and Blood Components Diane K. Hall Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.

Advertisements

Fouad Atouf, Ph.D. Director, Biologics & Biotechnology

Development of Guidance Documents Jennifer Scharpf, M. P. H

Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.

CBER Whole Blood and Blood Component Labeling Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.

Introduction to Regulation

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.

COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.

1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.

FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.

Requirements for Standardized Study Data: Update on Guidance Ron Fitzmartin, PhD, MBA Data Standards Program Office of Strategic Programs Center for Drug.

Denise K. Gavin, Ph.D. Division of Cellular and Gene Therapies

Office of Combination Products: Current Initiatives

DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,

Allergen regulation in the future : what will be the place for recombinant allergens ? Jacqueline DAYAN-KENIGSBERG European Academy of Allergology and.

Biotechnology Products & Regulatory requirements Medical Writer Group NL Naarden, 8 Dec 2005 H.F. Schuring.

Ensuring Product Quality in Gene Transfer Clinical Trials

Cellular Products for Cardiac Diseases Dwaine Rieves, MD Center for Biologics Evaluation and Research FDA Perspective on:

Regional Plan for Regulatory System For Blood, Blood Components and Blood Products Objective/Target: By 2012 all member states will have in place a functioning.

CBER Review Considerations on Source Plasma Vaccination Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

CBER 1 Establishment Submissions Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.

Investigational New Drug Application (IND)

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

Pharmaceutical Services Guidance Training CFR § , (a)(b)(1) F425.

Division of Hematology Basil Golding M.D. Division Director Site Visits 2010 Laboratories of Hemostasis, and Plasma Derivatives.

Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.

UNCLASSIFIED10/12/ :41 AM Slide 1 Division of Regulated Activities and Compliance.

Apheresis Blood Components

Topics discussed in the presentation

DEPARTMENT OF HEALTH Medicines Regulatory Affairs

Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.

1 Combination Products: Jurisdictional Issues MassMEDIC Presentation March 28, 2006 Janice Hogan, Esq. Partner Hogan & Hartson, LLP

Workshop Session 3 Questions 1 How would a control strategy look different in a traditional submission vs a QbD submission? How would parameters that are.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

Recombinant allergens: what needs to come next?. Where we are with natural allergens n All natural, mixes based largely on an unselective extraction of.

Chief, Gene Therapy Branch

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

FDA ICH Public Meeting 5630 Fishers Lane, Rockville, MD May 8, :30 am -- 2:00 pm Implementation of the CTD Update-Issues-Next Steps Justina A. Molzon,

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.

OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February 26, 2014.

Functional Vision Endpoints: OCTGT Perspective Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation and.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

INDEX WHAT IS ICH ? HISTORY INITIATION INTRODUCTION TOPICS QUALITY GUDILINES.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.

BIOTECHNOLOGY A Review. What is biotechnology? Any technological application that uses biological systems, living organisms or derivatives thereof, to.

Get Complete File From exam-dumps.html exam-dumps.html.

ISO/HL Specification: Individual Case Safety Report (ICSR) Release 2 Lise Stevens Data Standards Project Manager FDA CBER/ADRM Bioinformatics Support.

GMP IN THE CURRENT REGULATORY EMVIRONMENT

BSB Biomanufacturing CHAPTER 3 Biomanufacturing Processes

What are Biopharmaceuticals?

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

CTD Content Management

Appendix III: Scope of Service of CUHK Service Units

Introduction and Definitions

What are Biopharmaceuticals?

FDA GUI Summary of Contract Manufacturing Arrangement for Drugs: Quality Agreements November This summary was prepared by the Rx-360.

Integrated Summaries of Immunogenicity: An FDA Reviewer’s Wish List

محاضرة عامة التقنيات الحيوية (هندسة الجينات .. مبادئ وتطبيقات)

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

EU SUBMISSION BY Haripriya & Revathy.

VICH Guidelines on stability: OVERVIEW

VICH Guidelines on stability: OVERVIEW

Presentation transcript:

Implementation of the CTD: CBER’S Perspective May 8, 2001 Joan Wilmarth Blair, M.A. International Affairs Advisor CBER/FDA May 8, 2001 Joan Wilmarth Blair, M.A. International Affairs Advisor CBER/FDA CBER

International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use

International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use

BIOLOGICAL PRODUCTS REGULATED BY CBER Whole Blood Somatic Cell & Gene Therapy Blood Components Allergenic Extracts Plasma Derivatives Vaccines Monoclonal Antibodies Biotech Derived Therapeutics TissuesXenotransplantation Blood Related Devices PeptidesPeptides

Q6B: Specifications,Test Procedures & Acceptance Criteria for Biotechnological/ Biological Products Q6B: Specifications,Test Procedures & Acceptance Criteria for Biotechnological/ Biological Products Scope: “…apply to proteins & polypeptides, their derivatives, & products of which they are components (e.g., conjugates)” “…does not cover antibiotics, synthetic peptides & polypeptides, heparins, vitamins, cell metabolites, DNA products, allergenic extracts, conventional vaccines, cells, whole blood, and cellular blood components” Scope: “…apply to proteins & polypeptides, their derivatives, & products of which they are components (e.g., conjugates)” “…does not cover antibiotics, synthetic peptides & polypeptides, heparins, vitamins, cell metabolites, DNA products, allergenic extracts, conventional vaccines, cells, whole blood, and cellular blood components”

BIOLOGICAL PRODUCTS REGULATED BY CBER Whole Blood Somatic Cell & Gene Therapy Blood Components Allergenic Extracts Plasma Derivatives Vaccines Monoclonal Antibodies Biotech Derived Therapeutics TissuesXenotransplantation Blood Related Devices ICH PeptidesPeptides

Whole Blood Somatic Cell & Gene Therapy Blood Components Allergenic Extracts Plasma Derivatives Vaccines Monoclonal Antibodies Biotech Derived Therapeutics TissuesXenotransplantation Blood Related Devices ICH CTD? PeptidesPeptides CTD application format only applicable to BLAs for this subset of products? CTD application format only applicable to BLAs for this subset of products?

BLA - Section Application for Biologics Licenses l Describes content of application l Describes procedures for filing

NDA - Section Content and Format of Application l Describes form and content, e.g., – Application form – Numbers of copies (archival copy) – Index – Summaries – Case report tabulations – Case report forms – Labeling – etc.

The question is NOT “Will CBER be accepting the CTD instead of the BLA?” The question being asked is “Will the CTD application format be applicable to all BLAs?”

Application Format - Regulatory Requirements? NDA - Section l Describes content of application l Describes procedures for filing l Describes format BLA - Section l Describes content of application l Describes procedures for filing l DOES NOT describe format

BLA req’ments and Form 356h format BLA req’ments and Form 356h format ELA/PLA Req’ments ELA/PLA Req’ments Migration from ELA/PLA to BLA Construct Issue guidance for content & format for product categories Issue guidance for content & format for product categories

BLA/Form 356h  Issuance of Guidances l 8/96: Therapeutic rDNA-derived products and monoclonal antibody products for in vivo use l 1/97: Autologous somatic cell therapy products l 1/99: Vaccines & related products l 2/99: Plasma derivatives, animal plasma, serum-derived products l 3/99: Biological in-vitro diagnostics l 4/99: Allergenic extracts or allergen patch tests l 5/99: Human blood & blood components

CTD BLA BLA Content Req’ments “CMC” guidance BLA Content Req’ments “CMC” guidance Formatting of BLA to CTD Construct Revise guidance for new format Revise guidance for new format

CBER’s Acceptance of CTD l Question of acceptance of CTD format prior to issuance of guidance l Use of CTD format not precluded in advance of guidance l URGE early communication -- assure all required content included in submission

CBER’s CTD Implementation Process l Revise “CMC” guidances to map CTD to BLA l “Specified Products” currently in process l Staff training l Workshops likely

Integration of CTD with Applications for Product Approval